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Summary Background: Community-onset infections caused by methicillin-resistant
Staphylococcus aureus (COMRSA) are being increasingly reported worldwide.
Methods: A retrospective study was performed of 14 patients with 15 episodes
of COMRSA bacteremia (COMRSAB) admitted to the Royal Darwin Hospital, Northern
Territory, Australia from 1998 to 2001. Isolates from COMRSAB episodes underwent ex-
tended susceptibility testing and molecular typing by pulsed ﬁeld gel electrophoresis
and allotyping of the staphylococcal cassette chromosome mec (SCCmec) region by
polymerase chain reaction.
Results: The proportion of community-onset S. aureus bacteremia episodes that
were due to COMRSA increased from 9% in 1998 to 20% in 2001. The clinical features
of COMRSAB were similar to those seen with methicillin-susceptible strains, including
sepsis, endocarditis and metastatic infection. Ineffective empiric antimicrobial ther-
apy was administered in the majority (80%) of episodes. All COMRSAB isolates tested
contained allotype IV SCCmec, which is commonly found in community isolates of
MRSA and rarely found in isolates from healthcare-associated MRSA infection.
Conclusion: The increasing incidence of COMRSAB in our region has resulted in the
addition of vancomycin to standard empiric therapy in certain patients with suspected
S. aureus bacteremia acquired in the community.
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rights reserved.
 Presented in part at the 8th Western Paciﬁc Congress on Chemotherapy and Infectious Diseases, Perth, Australia 2002 and at
the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA 2003. Supported in part by a grant
from the Royal College of Pathologists of Australasia.
*Corresponding author. Tel.: +61-8-9224-2444; fax: +61-8-9224-1989.
E-mail address: ronan.murray@health.wa.gov.au (R.J. Murray).
1201-9712/$30.00 © 2004 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.ijid.2003.11.008
276 R.J. Murray et al.
Introduction
Bacteremia caused by the ubiquitous human
pathogen Staphylococcus aureus is a common cause
of morbidity and mortality worldwide.1,2 Until re-
cently, the great majority of cases of S. aureus bac-
teremia acquired in the community setting were
caused by methicillin-susceptible strains (MSSA),
whereas methicillin-resistant strains (MRSA) were
primarily encountered in hospitalized patients,
long-term care facilities or amongst cohorts of in-
travenous drug users.3,4 During the past decade
we have witnessed a signiﬁcant increase in the
incidence of infection caused by MRSA in North-
ern Australia in individuals who have had no prior
association with healthcare institutions.5—7 This
concerning development has also been reported
from several other regions worldwide.8—14 These
‘community-onset’ MRSA (COMRSA) strains dif-
fer from the majority of healthcare-associated
MRSA strains in that they are typically suscep-
tible to several non-β-lactam antistaphylococcal
agents.6 COMRSA strains appear capable of causing
a similar spectrum of infection to that seen with
MSSA, including invasive disease.8—13 In addition,
COMRSA have the potential to cause toxin-mediated
disease.14—16
Staphylococcal cassette chromosome mec
(SCCmec) is a distinct genetic element found ex-
clusively in methicillin-resistant staphylococci.17,18
The core components of SCCmec are (1) the
mec complex, which consists of the mecA gene
that codes for production of the low-afﬁnity
penicillin-binding protein PBP2a and the regulatory
genes mecR1 and mecI, which are inducers and re-
pressors of mecA expression respectively; and (2)
the cassette chromosome recombinase (ccr) gene
complex, the products of which are proteins which
facilitate site-speciﬁc excision and integration of
SCCmec into the staphylococcal chromosome.17,18
Four allotypes of SCCmec have been deﬁned ac-
cording to the type of mec and ccr gene complexes
they carry and the presence or absence of a frag-
ment of the insertion sequence IS1272.17—19 Allo-
types I, II or III SCCmec are typically present in
healthcare-associated MRSA isolates, whereas allo-
type IV SCCmec has been found in COMRSA isolates
from the United States and Australia.20,21
The purpose of this study was to describe the clin-
ical, epidemiological and molecular genetic aspects
of community-onset MRSA bacteremia (COMRSAB)
presenting to the Royal Darwin Hospital (RDH),
Northern Territory, Australia between 1998 and
2001 and to determine whether current recommen-
dations for empiric therapy of suspected S. aureus
bacteremia are appropriate in this population.
Patients and methods
Subjects and setting
Patients with community-onset S. aureus bac-
teremia (SAB) admitted to the Royal Darwin Hos-
pital (RDH) were retrospectively identiﬁed from a
database maintained by the Department of Infec-
tion Control. RDH is the only tertiary referral insti-
tution in the tropical ‘Top End’ of the Northern Ter-
ritory and services a population of approximately
150,000, one-third of whom reside in remote or ru-
ral locations. Approximately 25% of the population
identify themselves as Aboriginal. Approval for the
study was granted by the Top End Human Research
Ethics Committee with the study being conducted
as a quality assessment exercise.
Deﬁnitions
An episode of SAB was deﬁned as the presence of
S. aureus in one or more sets of blood cultures
(BACTEC PLUS AEROBIC/F, PLUS ANAEROBIC/F and
PEDS PLUS/F, BACTEC 9000 Fluorescent Series Sys-
tems, Becton Dickinson, Sparks, MD) in association
with a clinical history consistent with bacteremia
as determined by the authors. An episode of SAB
was considered to be ‘community-onset’ if it be-
came manifest less than 48 hours following admis-
sion in an individual who had not been a hospital
inpatient or resident in a long-term care facility in
the 90 days prior to admission.
Clinical data
Episodes of COMRSAB were identiﬁed from the
infection control bacteremia database and the
corresponding medical records were reviewed. In
addition to demographic, clinical and laboratory
investigation parameters, the time of commence-
ment, dose, route of administration and duration of
antimicrobial agents administered in each episode
while the patient was an inpatient or undergoing
outpatient intravenous antimicrobial therapy was
obtained from inpatient medical records, prescrip-
tion charts, or on referral documents if antimicro-
bials had been administered prior to attendance at
RDH. Empiric antimicrobial therapy for COMRSAB
(i.e., therapy commenced prior to the results of
susceptibility testing being known) was considered
‘effective’ if it contained vancomycin (alternative
parenteral agents active against MRSA such as te-
icoplanin, quinupristin-dalfopristin and linezolid
were not available at RDH during the study pe-
riod), and ‘ineffective’ if it contained no agents
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with reliable in vivo activity against COMRSA (e.g.,
an antistaphylococcal β-lactam with or without
an aminoglycoside). A diagnosis of endocarditis
was made according to the modiﬁed Duke criteria
proposed by Li et al.22
Organism identiﬁcation and
susceptibility testing
Staphylococcus aureus was identiﬁed by standard
laboratory methods. The identity of the isolate
was conﬁrmed by a commercial automated iden-
tiﬁcation system which simultaneously performed
susceptibility testing by broth microdilution (Rapid
POS Combo Tray, MicroScan WalkAway96, Dade
Behring, Deerﬁeld, IL). Methicillin resistance was
extrapolated from results obtained for oxacillin in
accordance with NCCLS guidelines (MIC to oxacillin:
>2mg/L by broth microdilution).23
Disc diffusion susceptibility testing for 13 an-
timicrobial agents was also performed in or-
der to test antistaphylococcal agents that are
not represented in the Rapid POS Combo Tray
(quinupristin-dalfopristin, linezolid and fusidic
acid) and to demonstrate inducible resistance to
clindamycin. Testing and zone size interpretation
was performed according to NCCLS guidelines for
all agents apart from fusidic acid. Disc diffusion
susceptibility testing for fusidic acid was performed
and interpreted according to previously published
criteria.24 Discs containing clindamycin and ery-
thromycin were placed 20mm apart on the same
plate in order to detect inducible resistance to
clindamycin (IRC) as described previously.25
Isolates that were resistant to methicillin and
two or less of the non β-lactam agents tested were
termed non-multiple resistant methicillin-resistant
S. aureus (nmrMRSA). Isolates that were re-
sistant to methicillin and more than two non
β-lactam agents were termed multiple-resistant
methicillin-resistant S. aureus (mrMRSA). These
deﬁnitions were in accordance with deﬁnitions
from previously published studies of COMRSA infec-
tion in the region.5,6
Chromosomal DNA macrorestriction analysis
by pulsed-ﬁeld gel electrophoresis (PFGE)
Ten isolates from nine episodes of COMRSAB in
eight patients were available for molecular typing.
Agarose plug formation and digestion with SmaI
restriction enzyme was performed according to a
previously described protocol for MRSA.26 PFGE was
performed using the CHEF DRIII system (Bio-Rad
Laboratories, Hercules, CA). The run parameters
were: 200 V, switch time 1—40 s, duration 20 h. The
resultant gels were imaged and analyzed by direct
visual inspection according to the criteria estab-
lished by Tenover and colleagues27 in addition to
automated analysis using Multi-Analyst (Bio-Rad
Laboratories).
SCCmec allotyping
COMRSAB isolates typed by PFGE and three ad-
ditional isolates from patients with healthcare-
associated mrMRSA bacteremia underwent SCCmec
allotyping by polymerase chain reaction (PCR) using
a previously described method.28 SCCmec allotypes
were assigned according to the genotypes of mec
and ccr complexes that were identiﬁed according
to the following criteria which have been described
previously: Allotype I = type 1 ccr and class B mec
(mecA - mecR1-IS1272); allotype II = type 2 ccr
and class Amec (mecA-mecR1-mecI); allotype III=
type 3 ccr and class A mec; and allotype IV =
type 2 or 4 ccr and class A mec.17,18
Results
Between 1998 and 2001, 121 episodes of community-
onset SAB were identiﬁed in individuals admitted
to RDH. Of these, 23 episodes (19%) were due to
MRSA. Eight of these 23 episodes occurred in pa-
tients with indwelling central venous catheters
and were excluded from further analysis. There-
fore 15 episodes of COMRSAB were identiﬁed in
14 patients, which represented 12% of all episodes
of community-onset SAB that occurred during the
study period. All cases of COMRSAB were due to
nmrMRSA. The proportion of community-onset SAB
episodes that were due to COMRSA increased from
9% in 1998 to 20% in 2001 (Figure 1), however this
difference did not reach statistical signiﬁcance
(p = 0.46 by Fisher’s Exact Test).
The mean age of patients with COMRSAB was 39
years (range: two months to 80 years); 71% of pa-
tients were female. Twelve of the 14 patients (86%)
identiﬁed themselves as Aboriginal and 11 of the 14
(79%) resided in remote or rural areas of the Top End
of the Northern Territory. Three patients required
urgent evacuation from remote areas by air to RDH
for further management.
Clinical features
In 12 episodes of COMRSAB (80%), fever was the
primary symptom on presentation. Rigors were
reported or witnessed in a minority of episodes
(27%). An identiﬁable source of the bacteremia
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Figure 1 Resistance pattern of isolates from episodes
of community-onset Staphylococcus aureus bac-
teremia the Royal Darwin Hospital between 1998 and
2001. MSSA: methicillin-susceptible S. aureus; MRSA:
methicillin-resistant S. aureus.
was identiﬁed on admission in all episodes: in ﬁve
episodes there were wounds or lacerations with-
out cellulitis, four had cellulitis in association with
wounds or lacerations, three had scabies infesta-
tion with secondary bacterial infection, two had
skin or soft tissue abscesses, and in one episode
there was a history of recent intravenous drug use.
In 12 of the 15 episodes (80%) the patient had a body
temperature of ≥38 ◦C, and clinical ﬁndings consis-
tent with septicemia (pulse rate of ≥100 bpm as-
sociated with hypotension (systolic blood pressure
≤100mmHg, diastolic blood pressure ≤60mmHg)
were present in four of these 12 episodes.
Investigations
In eight episodes (53%), MRSA was cultured from
a site other than blood, including skin or soft tis-
sue (six episodes), and sputum, synovial ﬂuid and
urine (one episode each). In two episodes, more
than one organism was isolated from blood; in one
episode, both MRSA and MSSA were isolated, and
in another episode, Acinetobacter baumannii was
also isolated. Signiﬁcantly abnormal baseline inves-
tigation results included an elevation in the neu-
trophil count to ≥7.5× 109/L in 12 episodes (80%),
and an abnormal chest X-ray in three episodes (20%)
including radiographic evidence of lung abscess in
two episodes (13%).
Transthoracic echocardiography (TTE) was per-
formed in ﬁve of the 15 episodes (33%). In one
episode, both transesophageal echocardiography
and TTE were performed. A diagnosis of endocardi-
tis was made in three of the 15 episodes (20%),
including one case each of aortic, mitral and tricus-
pid endocarditis associated with mild, moderate,
and severe regurgitation, respectively.
Antimicrobial therapy
Empiric parenteral antimicrobial therapy was ad-
ministered to all patients with COMRSAB at the time
of presentation. In 13 of the 15 episodes (87%), em-
piric therapy was considered to be ineffective. Two
episodes (13%) were treated with effective empiric
antimicrobial therapy: in both episodes the patients
were admitted to the intensive care unit with a di-
agnosis of septic shock and in one of these episodes
there was a history of previous invasive COMRSA in-
fection.
Vancomycin was administered at some stage dur-
ing admission in 11 of the 15 COMRSAB episodes
(73%). The mean time from presentation with
COMRSAB to administration of vancomycin was
43.5 hours (range, 1—144 hours). The mean dura-
tion of vancomycin therapy was 24 days (range,
5—72 days). In four of the 15 episodes (27%), the
patient did not receive vancomycin at any stage of
their admission. Two of these episodes occurred in
infants with a readily apparent site of origin of the
bacteremia (scabies with secondary bacterial in-
fection and a scalp abscess): in one case, the blood
culture result was considered by the managing clin-
ician to represent contamination. In the other case,
susceptibility results had not been seen by the man-
aging clinicians prior to patient discharge, and the
infection failed to improve until the child was com-
menced on oral trimethoprim-sulfamethoxazole
in the community. The two other episodes where
vancomycin was not administered were in an adult
patient with infected superﬁcial thickness burns,
where the blood culture result was considered by
the managing clinician to represent contamination,
and in an adult patient with crusted scabies who re-
ceived six days of intravenous ticarcillin-clavulanic
acid and gentamicin in keeping with an established
hospital protocol for this condition.
Complications
Lesions consistent with metastatic foci were seen
in two episodes of COMRSAB, both of which were
multiple pulmonary lesions consistent with abscess
formation. Surgery was performed in ﬁve of the
15 episodes (33%), including mitral valve replace-
ment, knee joint lavage, debridement of burns, in-
cision and drainage of a cutaneous abscess, and
open drainage of a pancreatic abscess.
Of the three patients diagnosed with COMRSA en-
docarditis, one patient died despite valve replace-
ment surgery and two survived without surgery. The
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Figure 2 Chromosomal DNA macrorestriction analysis of isolates from ten episodes of COMRSAB following SmaI
digestion and pulsed-ﬁeld gel electrophoresis (PFGE). Band patterns in three pairs of lanes (lanes 1 and 2, lanes 5 and
6 and lanes 8 and 9) are indistinguishable. These represent two isolates from an individual with persistent bacteremia
nine days apart (S3048 and S3052); two episodes of bacteremia in the same individual separated by eight months
(lanes 5 and 6), and isolates from two epidemiologically unrelated individuals (lanes 7 and 8). NCTC8325 was used as
a control strain. The dendrogram is based on the Dice coefﬁcient of pattern similarity.
duration of vancomycin therapy in these cases was
72, 42 and ﬁve days respectively (the latter patient
having self-discharged against medical advice).
Gentamicin was also administered in all three of
these episodes (for one, three, and three days re-
spectively) and rifampicin (for 42 days) in addition
to vancomycin and gentamicin in one episode.
Outcome
In 11 of the 15 episodes (73%) the patient recov-
ered from COMRSAB with no obvious sequelae. One
patient self-discharged before planned therapy
could be completed: the patient re-presented eight
months later with recurrent COMRSAB, was treated
with vancomycin, and made a full recovery with
no obvious sequelae. Three patients died within
three months of the diagnosis of COMRSAB. One of
the three deaths was considered attributable to
the bacteremia; the other two deaths occurred in
patients with multiple pre-existing medical con-
ditions who were considered to have died from
the complications of these rather than from the
bacteremia.
Antimicrobial susceptibility testing
When the results of automated broth microdi-
lution and disc diffusion susceptibility test-
ing for the COMRSAB isolates were compared,
100% agreement was found for the ten antimi-
crobials tested by both methods (penicillin,
oxacillin, clindamycin, erythromycin, tetracycline,
trimethoprim-sulfamethoxazole, gentamicin, ri-
fampicin, ciproﬂoxacin and chloramphenicol).
All isolates tested were susceptible to gentam-
icin, clindamycin, ciproﬂoxacin, chlorampheni-
col, tetracycline, rifampicin and trimethoprim—
sulfamethoxazole by broth microdilution and disc
diffusion. In addition, all isolates were susceptible
to quinupristin/dalfopristin and linezolid by disc
diffusion. Two of the 15 isolates (13%) were resis-
tant to fusidic acid. Eight of the 15 isolates (53%)
were resistant to erythromycin, and in all cases
where the isolate tested resistant to erythromycin
but susceptible to clindamycin, inducible resistance
to clindamycin was demonstrated phenotypically
by erythromycin disc approximation.
Pulsed-ﬁeld gel electrophoresis
Ten isolates from eight patients with COMRSAB
were available for molecular typing. Three pairs of
isolates had indistinguishable PFGE patterns (Figure
2). One pair represented two isolates from a patient
with persistent bacteremia where the isolates were
cultured on the day of admission and again nine
days later. The second pair represented two isolates
from the one patient who presented with a second
episode of COMRSAB eight months after the initial
episode, which had been inadequately treated,
suggesting either relapse of the initial COMRSA
infection from a deep focus or recurrence of bac-
teremia caused by persistent skin carriage of a
single COMRSA strain. The ﬁnal pair of indistin-
guishable isolates were from episodes of COMRSAB
in individuals from different locations in the North-
ern Territory who presented several months apart.
SCCmec allotyping
All ten isolates from nine episodes of COMRSAB
that were available for testing contained allotype
IV SCCmec. In contrast, the three isolates from pa-
tients with hospital-acquired mrMRSAB were found
to contain type III SCCmec. One of the isolates from
a hospital-acquired mrMRSAB episode contained
a subclass of the class A mec complex (Class A1
mec complex) which results from a 166-bp deletion
in the membrane-spanning domain of the mecR1
gene.28
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Discussion
This study describes the largest cohort of individu-
als with community-onset MRSA bacteremia from a
single institution. Previous studies of COMRSA infec-
tion have included individuals with invasive disease
and/or bacteremia, however detailed analysis of
these cases was either not performed or included
only a small number of predominantly pediatric
cases.9—14,16 The ﬁndings of this study suggest that
the clinical features and outcomes of COMRSAB are
similar to those found in community-onset MSSA
bacteremia.2 Infection occurred in individuals of
all age groups and in both urban and remote re-
gions of the ‘Top End’. There was a readily iden-
tiﬁable source for the bacteremia in all episodes,
and in the majority of cases symptoms and signs of
bacteremia were apparent at the time of presen-
tation. Complications that are commonly seen in
patients with community-onset MSSA bacteremia
such as pulmonary abscesses, endocarditis and sep-
sis requiring multiple organ support were all seen
in the cohort. Three of the 14 patients (21.4%)
died within three months of the onset of the bac-
teremia, with death attributed to the bacteremia
in one case.
An increase in the proportion of cases of
community-onset SAB that were due to MRSA oc-
curred during the period of study (from 9% in 1998
to 20% in 2001). This occurred in parallel with a
progressive increase in the incidence of COMRSA
infection presenting to RDH over the same time
period.29 It has previously been recognised that
Aboriginal individuals have been overrepresented
in studies of COMRSA in communities across the Top
End of the Northern Territory and in the adjacent
regions of Western Australia, where MRSA carriage
rates can exceed 40%.7,30 This was reﬂected in
our study, where the majority (86%) of COMRSAB
episodes occurred in Aboriginal individuals. This
association has also been described in other in-
digenous communities 5,11—13 and it has been sug-
gested that this may be the result of antimicrobial
selection pressure caused by the widespread and
frequent use of β-lactams for the treatment of
skin and soft tissue infections, which are highly
prevalent in these communities due to inadequate
hygiene standards that result from socioeconomic
disadvantage.7,31
Susceptibility testing of isolates obtained from
COMRSAB episodes in this study suggests that a
wide range of non-β-lactam agents are reliably
active against COMRSA. However, most of these
agents do not exert reliable in vitro bactericidal
activity against S. aureus, which is generally con-
sidered to be critical in the setting of bacteremia.
Clindamycin is often considered a useful agent for
infections due to COMRSA, and all of our isolates
tested susceptible to this agent. However, when
the isolate was resistant to erythromycin (as it was
in the majority of cases), inducible resistance to
clindamycin was demonstrated by disc approxima-
tion. Some authors have advised against the use
of clindamycin for infections caused by S. aureus
that exhibit inducible clindamycin resistance be-
cause of documented clinical failures of the agent
in this setting, which may be the result of the
emergence of constitutively resistant mutants dur-
ing therapy.25,32 The explanation for resistance to
fusidic acid in a signiﬁcant proportion of isolates is
unclear, particularly as this agent is rarely used in
our region; this ﬁnding has also been described in
studies of COMRSA in neighbouring regions.6
Current Australian recommendations for empiric
antimicrobial therapy in cases of septicemia ac-
quired in the community suggest the use of an an-
tistaphylococcal β-lactam in combination with an
aminoglycoside.33 Several patients with COMRSAB
in this study received empiric therapy in accor-
dance with these guidelines. It has been suggested
on the basis of in vitro studies that the combination
of an antistaphylococcal β-lactam with gentamicin
may provide effective therapy for invasive COMRSA
infections until the results of susceptibility testing
are known.34 However, given that clinical failures
have been reported with the use of aminoglycoside
monotherapy for staphylococcal bacteremia,35 it
could be believed that this approach would be
suboptimal therapy for serious infection due to
COMRSA. The time to institution of effective an-
timicrobial therapy in most episodes of COMRSAB
in this study was in the order of 48 to 72 hours.
This delay in therapy may increase the risk of mor-
bidity and mortality from bacteremia, as has been
described in hospital-acquired SAB.36 In the four
episodes of COMRSAB who did not receive appro-
priate therapy at any time during their admission,
three patients appeared to recover without obvious
sequelae. This suggests that
1. The isolate was a blood culture contaminant
(which was considered unlikely, as all had an
obvious source for their bacteremia, including
one episode where COMRSA was cultured from
another site); or
2. The antimicrobials administered were able to
clear the bacteremia (gentamicin was given for
six days in one episode); or
3. The individual was able to clear the bacteremia
spontaneously.
Because of the relentless increase in incidence
of infections caused by COMRSA in certain regions
Community-onset methicillin-resistant Staphylococcus aureus bacteremia in Northern Australia 281
in Australia, it has been proposed that vancomycin
should be given in addition to an antistaphylococcal
β-lactam for the empiric treatment of patients who
present with septicemia and are thought to be at
increased risk for COMRSA carriage.37 Although the
increase in the proportion of community-acquired
SAB due to COMRSA did not reach statistical sig-
niﬁcance over the period of study, it is believed
an increase in this proportion from 0% in the year
prior to the study [unpublished data] to 20% in
2001 supports a decision to recommend the use
of empiric vancomycin for patients who present
to RDH with suspected staphylococcal sepsis. As
evidence from in vitro and in vivo studies suggests
that vancomycin is inferior to antistaphylococ-
cal β-lactams for the treatment of invasive MSSA
infection,38—41 empiric therapy that includes both
an antistaphylococcal β-lactam and vancomycin
may be the most appropriate regimen in regions
such as ours where COMRSA is prevalent. However,
it is recognised that adopting this recommenda-
tion will have signiﬁcant implications for the wider
community including cost, lack of availability of
vancomycin in remote and rural areas, and the
potential for selection of vancomycin—resistant
bacteria. Quinupristin-dalfopristin or linezolid may
be acceptable alternatives to vancomycin for MRSA
infection, including bacteremia,42 however cost
considerations and adverse effect proﬁles may re-
sult in the use of these newer agents being limited
to those individuals with intolerance of vancomycin
or treatment failure. Rapid tests to detect the
presence of the mecA gene (which confers resis-
tance to antistaphylococcal β-lactams in S. aureus)
directly from clinical specimens such as blood or
pus may be useful in determining which patients
should receive vancomycin instead of a β-lactam
for empiric therapy.43
Strains of COMRSA isolated from bacteremic pa-
tients in this study appear to be able to cause
persistent or recurrent infection, as demonstrated
by indistinguishable PFGE patterns from isolates
cultured from the same patient at different points
in their clinical course. SCCmec typing of COMRSAB
isolates showed that all that were tested contained
allotype IV SCCmec. Because allotype IV SCCmec
does not contain any resistance determinants other
than mecA, COMRSA isolates are typically sus-
ceptible to most non-β-lactam antistaphylococcal
agents. By contrast, the three isolates from pa-
tients with hospital-acquired mrMRSA bacteremia
contained allotype III SCCmec, which is larger than
type IV SCCmec and contains extra resistance de-
terminants that confer resistance to antimicrobial
agents other than β-lactams. This is consistent
with the ﬁndings of previous studies of COMRSA
from geographically diverse regions in Australia
and the United States.19,20 It has been suggested
that COMRSA can occur if an MSSA strain acquires
SCCmec either from an established MRSA strain or
a coagulase-negative methicillin-resistant staphy-
lococci and become MRSA,20,44 which can then
become predominant with selective pressure from
β-lactam use.
Recently, multilocus sequence typing (MLST) of
MRSA strains from around the world has demon-
strated that major MRSA clones arise from success-
ful epidemic MSSA strains and that horizontal trans-
fer of SCCmec occurs relatively frequently between
staphylococci.20 Further characterization of these
isolates by several different typing methodologies,
including MLST, is being undertaken in order to de-
lineate more clearly the epidemiology of invasive
COMRSA infection in this region.
This study has several limitations. Firstly, the
retrospective design did not allow the assessment
of the impact of direct intervention (such as the
effect of antimicrobial advice from an Infectious
Diseases Physician/Clinical Microbiologist) on the
management and outcome of COMRSAB. Secondly,
a case-control study was not performed in order
to determine the risk factors for COMRSAB such
as prior antimicrobial use. Thirdly, the limited
numbers in this study meant that it could not be
determined whether COMRSAB was associated with
an increased risk of complications or adverse out-
come when compared to SAB caused by MSSA, or
whether a delay in effective antimicrobial therapy
was associated with additional morbidity and/or
mortality.
Further studies, including a case-control study
using matched cases of community-onset MSSA
bacteremia and prospective studies examining
outcomes with respect to empiric and deﬁnitive
antimicrobial regimens are required in order to
address these issues. Because it is possible for
MRSA colonisation to persist for many months, it
is possible that some of the cases of COMRSAB
that were described in this study acquired MRSA
following healthcare contact more than 90 days
before their admission with COMRSAB, or alter-
natively from close contact with another individ-
ual with a more recent healthcare contact, as
has been suggested in a recent meta-analysis of
COMRSA colonisation and infection.45 However,
as has been shown, MRSA acquired in the com-
munity differs from healthcare-associated MRSA
both phenotypically (non-multiresistant versus
multiresistant) and genotypically (type IV SCCmec
versus type III SCCmec) in the Northern Territory
region.19—21,28,30 It is likely that these infections
are truly community-acquired.
282 R.J. Murray et al.
Conclusions
In conclusion, the rapid and widespread emer-
gence of methicillin-resistant strains of S. aureus
in the community has inevitably resulted in a pro-
gressive and signiﬁcant increase in the number of
patients presenting to RDH with SAB that is resis-
tant to β-lactam antibiotics. This has resulted in
a change to empiric antimicrobial therapy guide-
lines for community-onset sepsis at RDH to include
vancomycin for individuals considered to be at
risk for COMRSAB. These ﬁndings also present a
signiﬁcant challenge to antimicrobial prescribing
practices in the community as a whole. The role of
newer antistaphylococcal agents such as linezolid
and quinupristin-dalfopristin in the management
of these life-threatening infections has yet to be
determined.
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